Abstract
A 60 years old male patient treated with Adalimumab for Crohn’s disease. The first lesions of the actinic keratosis type appeared on the forehead. The more lesions and tumours appeared. The patient noticed a tumor in the mid-forehead area that was larger than before. In the meantime, due to the relapse of the underlying disease (Crohn’s disease), 30 cm of the ileum was resected and Adalimumab was discontinued. This resulted in the theatrical progression of tumors in the median forehead region with numerous satellite nodules. In our patient, anti-TNF-α therapy could increase the risk of squamous cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND Study Group. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. J Crohns Colitis. 2016;10(11):1259–66. https://doi.org/10.1093/ecco-jcc/jjw152. Epub 2016 Aug 26
Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term efficacy and safety of adalimumab in pediatric patients with crohn's disease. Inflamm Bowel Dis. 2017;23(3):453–60. https://doi.org/10.1097/MIB.0000000000001021. PMID: 28129288; PMCID: PMC5319394
Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am. 2015;95(6):1105–22. https://doi.org/10.1016/j.suc.2015.07.006. Epub 2015 Sep 7
Belanouane S, Hali F, Baline K, Chiheb S, Marnissi F, Hliwa W. A rare case of malignant pyoderma associated with ulcerative colitis both treated effectively with adalimumab. Our Dermatol Online. 2020;11(4):393–6. https://doi.org/10.7241/ourd.20204.16.
Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005 Jul;4(4):637–41. https://doi.org/10.1517/14740338.4.4.637.
Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND Study Group. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a subanalysis of a prospective randomised clinical trial [DIAMOND Study]. J Crohns Colitis. 2019 Sep 19;13(9):1097–104. https://doi.org/10.1093/ecco-jcc/jjz030.
Kouklakis G, Efremidou EI, Pitiakoudis M, Liratzopoulos N, Polychronidis AC. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013;7:195–9. https://doi.org/10.2147/DDDT.S41889. Epub 2013 Mar 27. PMID: 23569358; PMCID: PMC3615922
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):119–30. https://doi.org/10.1002/pds.2046.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Brzezinski, P., Borowska, K. (2022). An Aggressive Skin Tumor in a Patient Treated with Adalimumab for Crohn’s Disease. In: Waśkiel-Burnat, A., Sadoughifar, R., Lotti, T.M., Rudnicka, L. (eds) Clinical Cases in Scalp Disorders. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-93426-2_38
Download citation
DOI: https://doi.org/10.1007/978-3-030-93426-2_38
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-93425-5
Online ISBN: 978-3-030-93426-2
eBook Packages: MedicineMedicine (R0)